There are currently 955 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
HyperArc Registry Study
NCT05270707
Recruiting
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2023
Locations: University of Alabama, Birmingham, Alabama
Conditions: Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
Register for Updates
Rett Syndrome Registry
NCT05432349
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
ALL
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: University of Alabama, Birmingham, Alabama
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Register for Updates
CERENOVUS Neurothrombectomy Devices Registry
NCT05591183
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cerebral Stroke
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
NCT04640532
Recruiting
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology, Birmingham, Alabama
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: University of Alabama, Birmingham, Alabama
Conditions: End Stage Liver Disease
Register for Updates
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Chronic Myeloid Leukemia
Register for Updates